Moreover, anti‐angiogenic agents have been combined with CAR-T therapy and the preclinical research has shown that anti-mouse VEGF antibodies enhance CAR-T cell infiltration, inhibit tumor growth, and prolong the survival time of GBM-bearing mice compared with EGFRvIII-CAR-T cell therapy alone [251]. The gene discussed is VEGFA; the disease is neoplasm.